CSIMarket Company Name, Ticker, Competitors, else..
 
Nucana Plc  (NASDAQ: NCNA)
 
Price: $1.3450 $0.05 3.462%
Day's High: $1.3700000047683716 Week Perf: 1.89 %
Day's Low: $ 1.30 30 Day Perf: -11.51 %
Volume (M): 44,640 52 Wk High: $ 7.22
Volume (M$): $ 0 52 Wk Avg: $2.58
Open: $1.33 52 Wk Low: $1.21



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Nucana Plc is a clinical-stage biopharmaceutical company that develops and commercializes innovative oncology treatments. The company focuses on developing proprietary medicines based on its ProTide technology, which enables the potent transformation of nucleoside analogs into novel prodrugs. These prodrugs aim to improve the therapeutic index of cancer treatments by increasing their efficacy and reducing toxicities. Nucana's lead product candidate, Acelarin, is currently being evaluated in clinical trials for multiple cancer indications, including colorectal and ovarian cancers. The company is committed to advancing the field of oncology and improving patient outcomes through the development of novel and targeted therapies.


   Company Address: NuCana plc Edinburgh 0
   Company Phone Number: 357 1111   Stock Exchange / Ticker: NASDAQ NCNA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
HCM        5.26% 
PTGX   -1.47%    
TGTX        1.85% 
WVE   -2.14%    
XNCR        0.52% 
ZLAB        7.28% 
• View Complete Report
   



Clinical Study

Evaluating NUC-7738s Potential Against Competitors Amidst Revenue Declines Insights from ESMO Congress 2025

Published Mon, Oct 20 2025 7:33 AM UTC

: This article aims to present an analysis of the latest findings regarding NUC-7738, a promising therapeutic modality developed by Nucana Plc, as showcased at the ESMO Congress 2025. The article will shed light on the encouraging data related to the drug s efficacy in combination with PD-1 inhibitors, juxtaposed with the company’s recent financial performance compared ...
Clinical Study

NuCanas Dual Approach Revealing Promising Insights for NUC-3373 with Pembrolizumab as Challenges in Colorectal Can...

Published Tue, Oct 14 2025 3:54 PM UTC

In a significant development for oncology, NuCana plc has announced encouraging preliminary data from their ongoing clinical trials investigating NUC-3373, a novel chemotherapy agent designed to treat various cancers, specifically in combination with Pembrolizumab, an anti-PD-1 therapeutic. The results highlight not only the compelling efficacy of this combination in heavily...
Product Service News

The Ascendant Potency of Innovation NuCana plc Secures Patent for NUC-7738 Amidst Challenging Financial Winds

Published Wed, Sep 25 2024 8:01 PM UTC

In the venerated halls of scientific inquiry and pharmaceutical advancement, there emerges a beacon of promise as NuCana plc, that eminent biopharmaceutical entity headquartered in the fair city of Edinburgh, recently proclaimed the auspicious grant of a composition-of-matter patent from the distinguished United States Patent and Trademark Office (USPTO). This noteworthy pat...
Clinical Study

Balancing Hope and Financial Reality The Case of NUC-7738 in Melanoma Treatment

Published Sat, Sep 14 2024 7:01 AM UTC

As the fight against melanoma continues, innovative therapeutic combinations are critical for managing patients who are refractory or resistant to existing treatments. Nucana Plc s recent presentation at the ESMO Congress 2024 highlights promising results for NUC-7738 in combination with pembrolizumab. However, the company faces financial challenges that cast a shadow on th...
Clinical Study

NuCanas Turning Point Discontinuation of NuTide323 Amidst Strategic Reassessments in Colorectal Cancer Treatments

Published Thu, Aug 29 2024 8:01 PM UTC

NuCana Plc has recently taken a critical step in its clinical development strategy by announcing the discontinuation of its Phase 2 randomized colorectal cancer study, referred to as NuTide:323. This decision follows a pre-planned initial analysis and recommendation from the study s steering committee, highlighting a potential pivot in the company’s focus and resources. K...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 5.43
Working Capital Ratio 5.56
Leverage Ratio (MRQ) 0.23
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.12 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -5,910,134
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.